Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in non-small-cell lung cancer (NSCLC), breast cancer, and colorectal cancer. Biomarker-associated therapies cater to both large and niche patient subpopulations within these common oncology indications. Although these therapies offer the advantage of selecting the patients who are most likely to respond to targeted therapy, typically they are premium-priced and subject to payer restrictions and cost-containment strategies.
GEOGRAPHY: United States.
PRIMARY RESEARCH: Survey of 101 U.S. medical oncologists and 30 U.S. MCO pharmacy directors and medical directors (PDs/MDs).
KEY DRUGS COVERED: Keytruda, Opdivo, Yervoy, Tecentriq, Enhertu, Perjeta, Kadcyla, Margenza, Nerlynx, Tukysa, Lynparza, Erbitux, Vectibix, Braftovi, and Stivarga.
U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.